The NHS can prescribe the new non-hormonal daily pill fezolinetant (Veoza by Astellas Pharma) for hot flashes and night sweats if hormone replacement therapy is not suitable. The National Institute for Health and Care Excellence (NICE) has recommended this medicine for the treatment of moderate to severe vasomotor symptoms caused by menopause in women in England and Wales. Fezolinetant was approved by the Medicines and Healthcare Products Regulatory Agency in December 2023. It is a neurokinin 3 receptor antagonist that blocks the nerve pathways in the brain that trigger these symptoms. A 45 mg tablet is taken once a day. Evidence comes from the clinical trials Daylight, Skylight 1 and Skylight 2, which noted a significant reduction in the frequency and severity of vasomotor symptoms compared to placebo. The Daylight study was published in The BMJ.